Shares of Gilead Sciences Inc. GILD inched 0.04% higher to $92.38 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6 ...

Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.34 which represents a slight increase of $1.75 or 1.93% from the prior close of $90.59. The stock opened at $91.35 and ...

Shares of Gilead Sciences Inc. GILD shed 1.67% to $90.59 Monday, on what proved to be an all-around dismal trading session ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City ... For more information please view the Barchart Disclosure ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

Gilead Sciences, Inc. and Tubulis have announced that they have entered into an exclusive option and license agreement to ...